Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Its Share Price
You may think that with a price-to-sales (or “P/S”) ratio of 0.3x Biofrontera Inc. (NASDAQ:BFRI) is definitely a stock worth checking out, seeing as almost half of all the Pharmaceuticals companies in the United States have P/S ratios greater than 4.9x and even P/S above 19x aren’t out of the ordinary. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s so limited.
See our latest analysis for Biofrontera
